Suzhou Precision Biotech was founded in 2016, located in Suzhou Industrial Park of biomedicine, originated from the intestinal microbiology project of Berkeley and Gates Foundation, focusing on human intestinal microbial treatment of artificial intelligence pharmaceutical, the company relies on advanced microbiome technology, data-driven new drug discovery. Is the world's leading living bacteria innovative drug research and development company. The company has research and development centers in Suzhou and San Francisco, and pilot cGMP workshop and independent medical laboratory (medical institution) in Jiangxi. At present, the core team of the company is composed of a team of professionals engaged in molecular biology, microbiology and computational biology, with rich experience in international drug research and development. Focusing on microbiome technology, the company has established three technology platforms (microDATA), microSYNTHESIS and micromolecular targeted drug discovery for human microbiome and disease. Through cooperation with clinicians, tens of thousands of microbiome data have been accumulated, and through culture omics, thousands of microbial strains with potential for new drugs and their intestinal microbial metagenomic data have been accumulated. Five live bacterial drugs have been developed, among which the new anticancer drug PRS217 and the new inflammatory bowel disease treatment PRS207 are about to enter clinical studies.
At present, Precision Biotech has obtained 3 core invention patents, 4 utility model patents and 2 software Copyrights. The company has cooperated with the 301 Hospital of the General Hospital of the People's Liberation Army, Peking Union Medical College Hospital, Shanghai Ruijin Hospital, the First Affiliated Hospital of Zhengzhou University, the First Affiliated Hospital of Soochow University, the Second Affiliated Hospital of Soochow University, the Children's Hospital of Soochow University, the People's Hospital of Jiangsu Province, the University of California at Berkeley and many other domestic and foreign institutions in scientific research and product development. Cooperation agreements have been reached with 20 enterprises, including Hangzhou Kaisheng E-commerce Co., LTD. (Entertiger), Changzhou Helsi Medical Out-patient Department Co., LTD., and Suzhou Zean Gene Technology Service Co., LTD.
Our vision is to create medicines by heart, to promote health, and to address unmet clinical needs.